In:
Hepatology Research, Wiley, Vol. 52, No. 3 ( 2022-03), p. 269-280
Abstract:
To assess the impact of clinical factors on the safety and efficacy of atezolizumab plus bevacizumab (ATZ + BV) treatment in patients with unresectable hepatocellular carcinoma (u‐HCC). Method Ninety‐four u‐HCC patients who were treated with ATZ + BV at multiple centers were enrolled. We defined Child‐Pugh (CP)‐A patients who received ATZ + BV treatment as a first line therapy as the ‘meets the broad sense of the IMbrave150 criteria’ group (B‐IMbrave150‐in, n = 46), and patients who received ATZ + BV treatment as a later line therapy or CP‐B patients (regardless of whether ATZ + BV was a first line or later line therapy) as the B‐IMbrave150‐out group ( n = 48). Patients were retrospectively analyzed for adverse events (AEs) and treatment outcomes according to their clinical characteristics, including neutrophil lymphocyte ratio (NLR) at baseline. Results The overall incidence of AEs was 87.2% (82/94 patients). The frequency of interruption of ATZ + BV treatment due to fatigue was higher in CP‐B than CP‐A patients ( p = 0.030). Objective response (OR) rates of the B‐IMbrave150‐in group (28.3%, 39.1%) were significantly higher than those of the B‐IMbrave150‐out group (8.3%, 18.8%; p = 0.0157, 0.0401) using Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST, respectively. In multivariate analysis, NLR (hazard ratio (HR), 4.591; p = 0.0160) and B‐IMbrave150 criteria (HR, 4.108; p = 0.0261) were independent factors associated with the OR of ATZ + BV treatment using RECIST. Conclusion In real‐world practice, ATZ + BV treatment might offer significant benefits in patients who meet B‐IMbrave150 criteria or have low NLR.
Type of Medium:
Online Resource
ISSN:
1386-6346
,
1872-034X
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
2006439-1
Permalink